__NUXT_JSONP__("/drugs/Darolutamide", (function(a,b,c,d,e){return {data:[{drug:{slug:a,emaEpar:[{activeSubstance:c,conditionIndication:"Nubeqa is indicated for the treatment of adult men with non metastatic castration resistant prostate cancer (nmCRPC) who are at risk of developing metastatic disease.",inn:c,marketingAuthorisationDate:"2020-03-27 01:00:00",marketingAuthorisationHolder:"Bayer AG",medicineName:d,url:"https:\u002F\u002Fwww.ema.europa.eu\u002Fen\u002Fmedicines\u002Fhuman\u002FEPAR\u002Fnubeqa"}],fdaDrugLabel:[{brand:"NUBEQA",indication:"1 INDICATIONS AND USAGE NUBEQA is indicated for the treatment of patients with non-metastatic castration resistant prostate cancer (nmCRPC). NUBEQA is an androgen receptor inhibitor indicated for the treatment of patients with non-metastatic castration-resistant prostate cancer. ( 1 )",manufacturer:"Bayer HealthCare Pharmaceuticals Inc.",splSetId:"1a7cb212-56e4-4b9d-a73d-bfee7fe4735e"}],id:a,nciThesaurus:{casRegistry:b,chebiId:b,chemicalFormula:b,definition:"A formulation containing an androgen receptor (AR) antagonist with potential antineoplastic activity. Darolutamide binds to ARs in target tissues; subsequently, inhibiting androgen-induced receptor activation and facilitating the formation of inactive complexes that cannot translocate to the nucleus. This prevents binding to and transcription of AR-responsive genes that regulate prostate cancer cell proliferation. This ultimately leads to an inhibition of growth in AR-expressing prostate cancer cells.",fdaUniiCode:"X05U0N2RCO",identifier:"C104748",preferredName:a,semanticType:"Pharmacologic Substance",subclassOf:["C146993"],synonyms:["Antiandrogen ODM-201","BAY 1841788","BAY-1841788","BAY1841788","DAROLUTAMIDE",a,d,"ODM 201","ODM-201"]},dir:"\u002Fdrugs",path:"\u002Fdrugs\u002FDarolutamide",extension:".json",createdAt:e,updatedAt:e}}],fetch:{},mutations:void 0}}("Darolutamide","","darolutamide","Nubeqa","2021-10-30T13:17:39.303Z")));